| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | ZIP3; ZIP-3 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human SLC39A3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SLC39A3抗体的参考文献示例(注：部分文献信息可能为模拟概括，实际引用需核实准确性)：
1. **"SLC39A3/ZIP3 regulates zinc homeostasis in colorectal cancer progression"**
- 作者：Li, Y., et al.
- 摘要：研究通过SLC39A3抗体检测结直肠癌组织中ZIP3蛋白表达水平，发现其表达下调与肿瘤转移和不良预后相关，提示SLC39A3可能通过调控锌稳态抑制癌症进展。
2. **"Zinc transporter ZIP3 modulates neuronal zinc homeostasis and neuroinflammation"**
- 作者：Smith, J., et al.
- 摘要：利用SLC39A3特异性抗体进行免疫荧光染色，发现ZIP3在小鼠脑神经元中高表达，敲除后导致锌离子失衡并加剧神经炎症反应，表明其在神经系统疾病中的作用。
3. **"SLC39A3 deficiency promotes epithelial-mesenchymal transition in breast cancer cells"**
- 作者：Wang, L., et al.
- 摘要：通过Western blot和免疫组化(使用SLC39A3抗体)证实，乳腺癌中ZIP3低表达与上皮-间质转化(EMT)标志物相关，提示其抑制肿瘤侵袭的潜在机制。
4. **"Functional characterization of SLC39A3 in pancreatic β-cell zinc transport"**
- 作者：Chen, R., et al.
- 摘要：研究采用SLC39A3抗体进行细胞定位分析，发现ZIP3定位于胰岛β细胞膜，调控锌离子内流并影响胰岛素分泌功能，为糖尿病治疗提供新靶点。
(注：以上文献为示例性概括，实际文献需通过PubMed、Web of Science等平台以"SLC39A3 antibody"或"ZIP3 antibody"为关键词检索获取。)
The SLC39A3 antibody is a research tool designed to detect and analyze the solute carrier family 39 member 3 (SLC39A3), a protein encoded by the SLC39A3 gene. SLC39A3. also known as ZIP3. belongs to the ZIP (Zrt-/Irt-like protein) family of zinc transporters, which facilitate the uptake of zinc and other metal ions across cellular membranes. This transmembrane protein is implicated in maintaining zinc homeostasis, a critical process for cellular functions such as enzyme activity, signaling, and gene regulation. Structurally, SLC39A3 contains eight transmembrane domains and is localized primarily in the plasma membrane or intracellular vesicles, depending on cell type and zinc availability.
Research on SLC39A3 has linked it to diverse physiological and pathological processes, including immune response, cancer progression, and neurological disorders. Dysregulation of zinc transport mediated by SLC39A3 has been observed in certain cancers, such as breast and prostate cancer, suggesting its potential role in tumorigenesis or metastasis. Additionally, SLC39A3 expression may influence inflammatory pathways and neurodegenerative conditions like Alzheimer’s disease.
The SLC39A3 antibody is widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study protein expression, localization, and interactions. Commercial antibodies are typically validated for specificity using knockout cell lines or siRNA knockdown. Researchers rely on this tool to explore SLC39A3’s mechanistic roles in health and disease, making it valuable for both basic and translational studies in molecular biology and biomedicine.
×
